Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.97 |
| ▸ | CHAT | P28329 | 1/20 | 0.97 |
| ▸ | TTR | P02766 | 2/20 | 0.65 |
| ▸ | FABP4 | P15090 | 1/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | NSD2 | O96028 | 2/20 | 0.50 |
| ▸ | CASP6 | P55212 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382721 | 0.99 | SNCA (1.00) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL64271 | 0.99 | SNCA (1.00) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL30261938 | 0.99 | SNCA (1.00) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL20574382 | 0.97 | SNCA (0.97) | SNCACHATTTRFABP4CCNA2 | |
| Pyrophosphoric Acid SCHEMBL31296093 | 0.89 | SNCA (0.81) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL30449729 | 0.84 | SNCA (0.75) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL12177963 | 0.84 | SNCA (0.75) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL11508403 | 0.84 | SNCA (0.75) | SNCACHATTTRFABP4CCNA2 | |
| Potassium Ion SCHEMBL1082232 | 0.83 | SNCA (0.72) | SNCACHATTTRFABP4CCNA2 | |
| Potassium Ion SCHEMBL29360751 | 0.83 | SNCA (0.72) | SNCACHATTTRFABP4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023079052-A1 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| WO-2023121036-A1 | VACCINE COMPOSITION COMPRISING INACTIVATED PNEUMOCOCCAL MUTANT STRAIN | 일동제약 주식회사 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023079052-A1 | METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES | PAIA BIOTECH GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
| US-20220275058-A1 | PURIFICATION OF FACTOR VIII SUBSPECIES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-01 | — | — | US | disclosed |
| US-20220152090-A1 | METHOD FOR TREATING AMYLOIDOGENIC DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2022-05-19 | — | — | US | disclosed |
| US-11286233-B2 | Stilbene derivatives for the treatment of CNS and other disorders | Ambient Photonics, Inc. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210114976-A1 | Stilbene Derivatives for the Treatment of CNS and Other Disorders | Ambient Photonics, Inc. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3642225-A1 | PURIFICATION OF FACTOR VIII SUBSPECIES | Baxalta Incorporated (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10590100-B2 | Benzofuran derivatives for the treatment of CNS and other disorders | Ambient Photonics, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190142713-A1 | Optical Evanescent Color Change Compositions and Methods of Making and Using the Same | SEGAN INDUSTRIES, INC. | 2019-05-16 | — | — | US | disclosed |
| EP-3443042-A1 | OPTICAL EVANESCENT COLOR CHANGE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Segan Industries, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190033319-A1 | BINDING DOMAIN MAPPING | George Mason Research Foundation, Inc. (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2018234543-A1 | PURIFICATION OF FACTOR VIII SUBSPECIES | BAXALTA INCORPORATED (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20180346433-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2018-12-06 | — | — | US | disclosed |
| US-10126304-B2 | Binding domain mapping | George Mason Research Foundation, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| WO-2017180898-A1 | OPTICAL EVANESCENT COLOR CHANGE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | SEGAN INDUSTRIES, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20150338417-A1 | BINDING DOMAIN MAPPING | GEORGE MASON UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| US-20110008376-A1 | IMMUNOGENIC COMPOSITIONS CAPABLE OF ACTIVATING T-CELLS | CROSSBETA BIOSCIENCES B. V. (NL) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590100-B2 | Benzofuran derivatives for the treatment of CNS and other disorders | PMP22, CDR2, CLN6 | SNCA 15/4885CHAT 241/4885TTR 95/4885 |
| US-10126304-B2 | Binding domain mapping | SNRPE, HSPBP1, CNBP | SNCA 3751/4885CHAT 4801/4885TTR 2090/4885 |
| US-20210114976-A1 | Stilbene Derivatives for the Treatment of CNS and Other Disorders | CLN6, MAPT, PSEN2 | SNCA 17/4885CHAT 100/4885TTR 29/4885 |
| US-11286233-B2 | Stilbene derivatives for the treatment of CNS and other disorders | CLN6, MAPT, PSEN2 | SNCA 17/4885CHAT 100/4885TTR 29/4885 |
| US-20180346433-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF CNS AND OTHER DISORDERS | PMP22, CDR2, CLN6 | SNCA 15/4885CHAT 241/4885TTR 95/4885 |
| US-20190033319-A1 | BINDING DOMAIN MAPPING | SNRPE, HSPBP1, CNBP | SNCA 3751/4885CHAT 4801/4885TTR 2090/4885 |
| US-20190142713-A1 | Optical Evanescent Color Change Compositions and Methods of Making and Using the Same | ERCC1, XPA, ERCC5 | SNCA 430/4885CHAT 3248/4885TTR 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.